Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sequential Administration of 5-azacytidine (AZA) and Donor Lymphocyte Infusion (DLI) for Patients With Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) in Relapse After Allogeneic Stem Cell Transplantation.

NCT02017457 is registered in ClinicalTrials.gov with Carlos Graux, MD, PhD as lead sponsor.

NCT NCT02017457
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02017457 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sequential Administration of 5-azacytidine (AZA) and Donor Lymphocyte Infusion (DLI) for Patients With Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) in Relapse After Allogeneic Stem Cell Transplantation.
Lead sponsor
Carlos Graux, MD, PhD
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2013
Completion date
November 30, 2019
Enrollment
50 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

acute myelogenous leukemia, myelodysplastic syndrome